Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.24 | 0.46 | 0.02 | 0.00 |
| FCF Yield | -71.71% | -16.18% | -5.21% | -2.68% |
| EV / EBITDA | -0.90 | -3.67 | -17.20 | -26.41 |
| Quality | ||||
| ROIC | -51.64% | -18.60% | -67.32% | 43.24% |
| Gross Margin | 35.54% | -24.36% | 81.69% | 96.94% |
| Cash Conversion Ratio | 1.51 | 1.67 | 0.70 | 3.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.60% | -49.44% | 2,109,156.19% | 3,193,180.17% |
| Free Cash Flow Growth | -3.25% | -58.33% | -94.69% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | 0.94 | 1.12 | 0.24 |
| Interest Coverage | -31.69 | 0.00 | -29.92 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 118.58 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 57.15 | 29.64 | -947.33 | -974.71 |